| Literature DB >> 24024826 |
Susanne Mattsson1, Sven Alfonsson, Maria Carlsson, Peter Nygren, Erik Olsson, Birgitta Johansson.
Abstract
BACKGROUND: Approximately 20-30% of patients with cancer experience a clinically relevant level of emotional distress in response to disease and treatment. This in itself is alarming but it is even more problematic because it is often difficult for physicians and nurses to identify cancer patients who experience clinically relevant levels of anxiety and depression symptoms. This can result in persistent distress and can cause human suffering as well as costs for individuals and to the community.Entities:
Mesh:
Year: 2013 PMID: 24024826 PMCID: PMC3848442 DOI: 10.1186/1471-2407-13-414
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Figure 1Flowchart of the study. ICBT = Internet-based cognitive behavioral therapy.
Summary of the study’s instruments and the observation points at which they will be used
| HADS | At baseline and at 1, 4, 7, 10, 18 and 24 months |
| MADRS-S | At baseline and at 10 months |
| STAI-S | At baseline and at 10 months |
| ESSI | At baseline |
| NLEs | At baseline |
| EROS | At baseline and at 10 months |
| PCL-C | At baseline and at 10, 18 and 24 months |
| EORTC QLQ-C30 | At baseline and at 1, 4, 7, 10, 18 and 24 months |
| EORTC QLQ-BR231 | At baseline and at 1, 4, 7, 10, 18 and 24 months |
| EORTC QLQ-PR251 | At baseline and at 1, 4, 7, 10, 18 and 24 months |
| EORTC QLQ-CR291 | At baseline and at 1, 4, 7, 10, 18 and 24 months |
| FACIT-F | At baseline and at 1, 4, 7, 10, 18 and 24 months |
| ISI | At baseline and at 1, 4, 7, 10, 18 and 24 months |
| PTGI-SF | At 10 months |
| Health economic questionnaire | At 1, 4, 7, 10, 18 and 24 months |
| EQ-5D | At 2 weeks and 1, 4, 7, 10, 18 and 24 months |
| Patient satisfaction questionnaire | At 1, 4 and 10 months |
| Internet use questionnaire | At 1, 4, 7, 10, 18 and 24 months |
| Knowledge and strategies questionnaire | At 2 weeks and 1 and 10 months |
EORTC QLQ European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire, EQ-5D Euroqol 5D, EROS Environmental Reward Observation Scale, ESSI Enriched Social Support Inventory, FACIT-F Functional Assessment of Cancer Therapy: Fatigue, HADS Hospital Anxiety and Depression Scale, ISI Insomnia Severity Index, MADRS-S Montgomery-Åsberg Depression Rating Scale – Self-Report, NLEs Negative Life Events questionnaire, PCL-C Post-Traumatic Stress Disorder (PTSD) Checklist – civilian version, PTGI-SF Post-Traumatic Growth Inventory, Short Form, QLQ-Br25 Quality of Life Questionnaire with diagnosis-specific modules for breast cancer, QLQ-C30 Quality of Life Questionnaire, Core 30, QLQ-CR29 Quality of Life Questionnaire with diagnosis-specific modules for colorectal cancer, QLQ-PR25 Quality of Life Questionnaire with diagnosis-specific modules for prostate cancer, STAI-S State-Trait Anxiety Inventory – State anxiety subscale.
1 = if appropriate.